Cargando…
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer
Castrate-resistant prostate cancer (CRPC) is a disease where survival is poor and treatment is challenging. Over the past 3 years, significant advances in the field have been made with US Food and Drug Administration approval of new drugs for patients with CRPC. However, despite the presence of new...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928061/ https://www.ncbi.nlm.nih.gov/pubmed/24600234 http://dx.doi.org/10.2147/OTT.S53524 |